Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senators Durbin, Hatch To Work Together On AER Plan

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system

You may also be interested in...



Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21

Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21

Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel